169 related articles for article (PubMed ID: 27630324)
1. Malakoplakia of the Urinary Bladder in a Patient with Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: A Case Report.
Sachanas S; Pangalis GA; Karouzakis P; Koulieris E; Moschogiannis M; Kalpadakis C; Yiakoumis X; Rontogianni D
Anticancer Res; 2016 Sep; 36(9):4759-62. PubMed ID: 27630324
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
Mannis G; Wu D; Dea T; Mauro T; Hsu G
Am J Hematol; 2015 Feb; 90(2):179. PubMed ID: 24890909
[No Abstract] [Full Text] [Related]
3. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
Kreiniz N; Bejar J; Polliack A; Tadmor T
Hematol Oncol; 2018 Feb; 36(1):349-354. PubMed ID: 28156016
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
Jones J; Mato A; Coutre S; Byrd JC; Furman RR; Hillmen P; Osterborg A; Tam C; Stilgenbauer S; Wierda WG; Heerema NA; Eckert K; Clow F; Zhou C; Chu AD; James DF; O'Brien SM
Br J Haematol; 2018 Aug; 182(4):504-512. PubMed ID: 29873072
[TBL] [Abstract][Full Text] [Related]
5. Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.
Amin NA; Balasubramanian S; Saiya-Cork K; Shedden K; Hu N; Malek SN
Clin Cancer Res; 2017 Feb; 23(4):1049-1059. PubMed ID: 27535981
[No Abstract] [Full Text] [Related]
6. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW
JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
Kipps TJ; Fraser G; Coutre SE; Brown JR; Barrientos JC; Barr PM; Byrd JC; O'Brien SM; Dilhuydy MS; Hillmen P; Jaeger U; Moreno C; Cramer P; Stilgenbauer S; Chanan-Khan AA; Mahler M; Salman M; Eckert K; Solman IG; Balasubramanian S; Cheng M; Londhe A; Ninomoto J; Howes A; James DF; Hallek M
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):715-722.e6. PubMed ID: 31447270
[TBL] [Abstract][Full Text] [Related]
8. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
[TBL] [Abstract][Full Text] [Related]
9. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
[No Abstract] [Full Text] [Related]
10. Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.
Cavazzini F; Lista E; Quaglia FM; Formigaro L; Cavallari M; Martinelli S; Rigolin GM; Foà R; Cuneo A
Leuk Lymphoma; 2016 Nov; 57(11):2685-8. PubMed ID: 26999572
[No Abstract] [Full Text] [Related]
11. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
Gordon MJ; Churnetski M; Alqahtani H; Rivera X; Kittai A; Amrock SM; James S; Hoff S; Manda S; Spurgeon SE; Choi M; Cohen JB; Persky D; Danilov AV
Cancer; 2018 Aug; 124(15):3192-3200. PubMed ID: 29797667
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
Prezzo A; Cavaliere FM; Bilotta C; Pentimalli TM; Iacobini M; Cesini L; Foà R; Mauro FR; Quinti I
Leuk Res; 2019 Dec; 87():106233. PubMed ID: 31639635
[TBL] [Abstract][Full Text] [Related]
13. Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia.
Manukyan G; Turcsanyi P; Mikulkova Z; Gabcova G; Urbanova R; Gajdos P; Smotkova Kraiczova V; Zehnalova S; Papajik T; Kriegova E
Leuk Res; 2018 Sep; 72():113-119. PubMed ID: 30149317
[TBL] [Abstract][Full Text] [Related]
14. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA
Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970
[TBL] [Abstract][Full Text] [Related]
15. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Molica S
Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
[TBL] [Abstract][Full Text] [Related]
16. Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.
Jain P; Keating MJ; Wierda WG; Sivina M; Thompson PA; Ferrajoli A; Estrov Z; Kantarjian H; O'Brien S; Burger JA
Clin Cancer Res; 2017 May; 23(9):2154-2158. PubMed ID: 27797975
[No Abstract] [Full Text] [Related]
17. A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.
Suzuki T; Miyakoshi S; Nanba A; Uchiyama T; Kawamoto K; Aoki S
J Clin Exp Hematop; 2018 Sep; 58(3):136-140. PubMed ID: 30012921
[TBL] [Abstract][Full Text] [Related]
18. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Mato AR; Roeker LE; Allan JN; Pagel JM; Brander DM; Hill BT; Cheson BD; Furman RR; Lamanna N; Tam CS; Handunnetti S; Jacobs R; Lansigan F; Bhavsar E; Barr PM; Shadman M; Skarbnik AP; Goy A; Beach DF; Svoboda J; Pu JJ; Sehgal AR; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Rhodes J; Ujjani CS; Nabhan C
Am J Hematol; 2018 Nov; 93(11):1394-1401. PubMed ID: 30132965
[TBL] [Abstract][Full Text] [Related]
20. Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.
Pleyer C; Sun C; Desai S; Ahn IE; Tian X; Nierman P; Soto S; Superata J; Valdez J; Lotter J; Wiestner A
Leuk Lymphoma; 2020 Oct; 61(10):2375-2382. PubMed ID: 32508208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]